Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

Key Takeaways Sanofi will acquire BPMC for up to $9.5B, including a 27% premium and CVRs tied to BLU-808 milestones. The deal adds Ayvakit, which saw Q1 2025 sales of $149.4M and is projected to hit $2B by 2030. SNY aims to reduce Dupixent reliance by expanding its immunology portfolio through acquisitions.Sanofi (SNY) announced that it has entered into a definitive agreement to acquire Blueprint Medicines (BPMC) for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC are ...